We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
MIA: Made In Africa is an ethical food company pioneering in creating products within Africa. Cocoa is grown in Madagascar and instead of exporting the ingredients, MIA create fairly made finished products in conjunction with local communities.
days to go: Expired investment: £137,281
In My Kitchen is a platform that aims to bring together a network of professional and semi-professional chefs to sell their signature dishes and recipes online. The platform was founded in July 2020. In My Kitchen asserts that its business model holds precedence in a time where takeaways have grown in popularity in the UK because of COVID-19. It gives many chefs who have become unemployed or have fewer shifts for developing their creativity and skills whilst allowing them to earn through the gig-economy. The company has a network of more than 70 chefs across London, with backgrounds across a range of cuisines. With the investment received, the company will develop its team and company infrastructure.

Pitch Rated

31%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
EMIXIT has built a B2B ecommerce platform wholesaling products from UK suppliers directly to trade buyers across Europe. Over 40 brands with 250+ products have already registered on the platform paying a fee. EMIXIT allows buyers to make up mixed pallets from different suppliers, in their local language, over labelled and delivered to the door – a “one-stop-shop”. Their service is aimed at buyers from small retail or foodservice chains to large multiple supermarkets and hotel/restaurant chains. www.emixit.eu.
days to go: Expired investment: £58,320
Pomodoro e Basilico are a popular vegan artisan food stall with a loyal following and have been featured by major news outlets and celebrity chefs. They are looking to raise funds to launch London's first Italian, Vegan Deli-Bistro to fill the gap in the market for great, Italian inspired, vegan delis.
days to go: Expired investment: Withheld
Erpingham House is the UK’s largest vegan restaurant whose aim is to make plant-based dining into the mainstream and provide delicious, healthy food and drinks to people. The company has earned nationwide recognition and, it has been listed in The Times top 20 vegetarian restaurants. It has also been featured in The Guardian and on channel 4’s “what Britain bought.” EH has served over 12,000 customers in its first year and, it has risen to over 20,000 followers on Instagram. The funds will be used to expand the brand & open a second site in Brighton.
days to go: Expired investment: £192,280
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph